Reference

Withdrawal Recognition Reference

Recognize substance withdrawal across common classes, with observable findings, time courses, and escalation triggers.

Recognition reference, not a scoring tool. For severity, use your facility's validated instrument (CIWA-Ar, COWS, SOWS). When in doubt about safety, escalate.

Call now — any substance

Triggers for EMS, ED, or immediate medical escalation

Witnessed or suspected seizure
Confusion or hallucinations with unstable vital signs or fever
Chest pain, severe shortness of breath, or fainting
Suicidal statement with intent or plan
Pregnancy with any withdrawal symptoms
Inability to keep down fluids for 12+ hours, or signs of significant dehydration

Alcohol

Shaky, sweaty, anxious, fast pulse starting 6–12 hours after the last drink — can progress to seizures or delirium over 2–4 days.

Alcohol withdrawal can be life-threatening. Chronic heavy drinking quiets the brain's GABA system and ramps up its glutamate system; when alcohol disappears, the brain is left in net excitatory overdrive. Patients with a long heavy-use history, prior complicated withdrawals, or significant medical comorbidity belong in a medically supervised setting from the start.

Onset

6–12 hours after last drink

Peak

24–72 hours; delirium tremens typically 48–96 hours

Duration

Most symptoms resolve over 5–7 days. Sleep, mood, and autonomic symptoms can linger for weeks.

Time course

Alcohol withdrawal

Onset 6h–12h · Peak 24h–3d · Resolves 5d–7d

03d1w

Onset windowPeak / danger windowResolving

Seizure window: roughly 12–48 hours. Delirium tremens: typically 48–96 hours, can extend to day 5–7.

Timelines are general clinical ranges, not patient-specific predictions. Individual courses vary with dose, duration of use, metabolism, and co-occurring substances.

What you'd observe

Tier 1

First 6–24 hours

Hand tremor visible with arms outstretched
Sweating, flushed skin, mild fever
Resting heart rate trending above the patient's baseline (often >100)
Anxiety, irritability, restlessness — often described as 'jumpy'
Nausea, poor appetite, retching without much output
Difficulty falling or staying asleep
Mild headache, sensitivity to light or sound

Tier 2

Building (12–48 hours)

Coarse tremor visible at rest, not just with arms out
Drenching sweats requiring clothing/linen changes
Heart rate well above baseline, often 110–130; rising blood pressure
Brief visual, tactile, or auditory misperceptions with otherwise clear sensorium (alcoholic hallucinosis)
Mild disorientation to time or place that comes and goes
Repeated vomiting; can't reliably keep down fluids

Tier 3

Dangerous (24–96 hours)

Witnessed or suspected generalized seizure — most commonly in the first 48 hours
Frank delirium tremens: agitation, confusion, vivid hallucinations, sweating, fever, very high heart rate and blood pressure together
Severe vital sign abnormalities (HR persistently >130, systolic BP >180, or dropping mental status with unstable vitals)
Inability to protect airway, persistent vomiting with aspiration risk

Red flags — call now

Specific acute triggers for this substance

Witnessed seizure activity, or a brief loss of consciousness with tongue bite, incontinence, or postictal confusion
Confusion or hallucinations together with fever or unstable vitals
Cannot keep down any fluids for 12+ hours
Chest pain, irregular pulse, or shortness of breath
Pregnant patient with any withdrawal symptoms
Anyone with a prior history of withdrawal seizures or DTs who is symptomatic and not already in a medical setting

Standing risk factors that lower the threshold for a medical setting

Any prior withdrawal seizure or delirium tremens (history alone raises the floor — treat as higher-risk from the start)
Daily heavy drinking sustained over years; failed prior unsupervised attempts to stop
Pregnancy
Concurrent serious medical illness (cardiac, hepatic, seizure disorder, recent surgery, malnutrition, eating disorder)
Concurrent benzodiazepine, GHB, or barbiturate use (the timelines stack and mask each other)
Older adults — lower threshold for medical setting; baseline cognitive impairment masks early delirium

What to expect next 24–72 hours

If the patient is in a medical setting and well-managed, the worst usually passes between 48 and 96 hours. Sleep and autonomic symptoms (heart rate, blood pressure swings, sweating) often persist a week or more. Mood, sleep quality, and cravings can take weeks to settle — this protracted phase is when relapse risk is highest, and where outpatient support matters most.

Subtleties non-specialists routinely miss

Kindling: each prior detox episode tends to make the next one more severe. A patient on their fourth withdrawal does not look like a patient on their first.
Co-use with benzodiazepines, sleep medications, or GHB can obscure early severity and produce delayed deterioration — assume the longer timeline of the two substances.
Thiamine deficiency is common in heavy long-term drinkers. Standard inpatient practice is to give thiamine before glucose-containing fluids to avoid precipitating Wernicke's encephalopathy — facility protocols cover this.
Blood alcohol level on arrival does not tell you withdrawal severity. A symptomatic patient with a positive BAL is still in withdrawal relative to their tolerance and can deteriorate.

Documentation language (adapt, don't copy)

Patient reports last alcohol use [date/time]. Objective findings consistent with alcohol withdrawal include [tremor / diaphoresis / tachycardia / specific vital signs]. Risk factors for complicated withdrawal include [prior withdrawal seizures / DTs / heavy daily use over X years / pregnancy / comorbidity]. Recommend [validated severity scoring per facility protocol] and [medically supervised setting / continued outpatient monitoring with clear escalation plan].

Sample phrasing for a non-prescribing clinician's note. Replace bracketed items with your observations. Not a template for diagnosis or scoring.

Sources

• Mayo-Smith MF. JAMA. 1997;278(2):144–151. ASAM consensus on pharmacological management of alcohol withdrawal.
• Schuckit MA. N Engl J Med. 2014;371(22):2109–2113. Recognition and management of delirium tremens.
• Victor M, Adams RD. Res Publ Assoc Res Nerv Ment Dis. 1953;32:526–573. Foundational description of alcohol withdrawal phenomenology.
• SAMHSA TIP 45: Detoxification and Substance Abuse Treatment.

Special populations & mixed-substance situations

Pregnancy

Untreated opioid withdrawal in pregnancy can cause preterm labor and fetal distress. Alcohol and benzodiazepine withdrawal carry maternal seizure risk plus fetal risk. Any pregnant patient with withdrawal symptoms of any substance class warrants a medical setting and OB involvement — do not manage outpatient on a wait-and-see basis.

Older adults

Lower the threshold for a medical setting across the board. Baseline cognitive impairment can mask early delirium. Falls risk during tremor and orthostasis is amplified. Polypharmacy is the rule, and many interactions (benzodiazepines, opioids, antipsychotics, anticholinergics) complicate withdrawal assessment.

Polysubstance

When two substances are involved, assume the longer timeline and the more dangerous syndrome of the two. Alcohol + benzodiazepines: treat as benzodiazepine timeline (longer, less predictable). Opioids + stimulants: do not declare the patient stable when the loud opioid phase ends — the quiet, suicide-risk stimulant phase is just beginning. Fentanyl + anything: extend the watch window.

Serious medical comorbidity

Cardiac disease, COPD, seizure disorder, recent surgery, eating disorder, severe malnutrition, and active infection all lower the threshold for medical-setting withdrawal. The withdrawal itself may be manageable, but the comorbidity changes the margin for error.

General clinical education for non-prescribing clinicians to help recognize withdrawal and know when to escalate. Does not score severity, does not replace your facility's protocols, and is not medical or legal advice. For severity scoring and documentation, use the validated instrument your facility licenses — CIWA-Ar for alcohol, COWS for opioids, SOWS for patient self-report. For level-of-care decisions, follow your facility's framework.

Opioids

Flu-like misery — yawning, runny nose, gooseflesh, cramps, sweats, dilated pupils. Rarely fatal in healthy adults, but the post-detox overdose risk is the highest in the patient's life.

Opioid withdrawal is unpleasant but rarely life-threatening on its own in otherwise healthy adults. The real dangers are (1) abrupt or unsupervised cessation in pregnancy, where OB/addiction-prescriber coordination and MOUD are preferred; (2) severe dehydration from vomiting and diarrhea; and (3) the lost-tolerance overdose risk in the days and weeks after acute withdrawal resolves. Medications for opioid use disorder, especially methadone and buprenorphine, improve outcomes and lower overdose mortality — consider them early.

Onset

Heroin / IR oxycodone: 8–24 hours. Fentanyl: can be delayed and variable. Methadone: 24–48 hours.

Peak

Short-acting: 36–72 hours. Fentanyl: can peak later and run longer than older short-acting-opioid timelines. Methadone: 72–96 hours.

Duration

Acute symptoms 5–10 days for short-acting; methadone can run 14–21 days. Low energy, sleep disruption, and cravings persist weeks to months.

Time course

Heroin / IR oxycodone / hydrocodone

Onset 8h–24h · Peak 36h–3d · Resolves 5d–10d

03d1w10d

Onset windowPeak / danger windowResolving

Classic short-acting opioid pattern.

Fentanyl & analogues

Often delayed and variable; visual range is illustrative, not predictive.

03d1w2w3w

Onset windowPeak / danger windowResolving

Onset and peak can be delayed beyond older short-acting-opioid expectations. Plan for a longer watch window and defer induction timing to facility protocol / MOUD prescriber.

Methadone

Onset 24h–2d · Peak 3d–4d · Resolves 14d–21d

01w2w3w

Onset windowPeak / danger windowResolving

Long, slow course because of long half-life.

Timelines are general clinical ranges, not patient-specific predictions. Individual courses vary with dose, duration of use, metabolism, and co-occurring substances.

What you'd observe

Tier 1

First 6–12 hours after onset

Yawning in clusters, watery eyes, runny nose, sneezing
Gooseflesh and chills alternating with sweats
Pupils noticeably wider than expected for the room light
Restless legs, frequent position changes, can't sit still
Mild anxiety, irritability, dysphoria
Stomach unease, loss of appetite

Tier 2

Building (12–48 hours)

Deep muscle and joint aches; patient describes 'bones hurting'
Abdominal cramping; nausea with vomiting; loose stools or diarrhea
Visible tremor, marked restlessness, pacing
Insomnia, agitation, intense cravings
Heart rate and blood pressure trending above the patient's baseline

Tier 3

Concerning (24–96 hours)

Repeated vomiting and diarrhea with poor oral intake — risk of dehydration and electrolyte loss
Lightheadedness on standing, dry mucous membranes, decreased urine output
Marked autonomic findings (sustained tachycardia, elevated blood pressure)
Inability to keep down medications or fluids

Red flags — call now

Specific acute triggers for this substance

Can't keep down fluids for 12+ hours, or signs of significant dehydration (very low urine output, dizziness, dry mouth, weakness)
Pregnant patient with any opioid withdrawal symptoms
Chest pain, severe shortness of breath, or fainting
Suicidal statement with intent or plan
After-detox period: any return-to-use event should be treated as a high-risk overdose scenario — naloxone in the home, never use alone, consider rapid MOUD restart

Standing risk factors that lower the threshold for a medical setting

Pregnancy — do not advise abrupt or unsupervised stopping; coordinate OB/addiction-prescriber care
Significant cardiac, respiratory, or GI illness
Co-occurring stimulant use — psychiatric risk reappears after the opioid acute phase
Recent release from incarceration or recent completion of detox (lost tolerance — overdose risk is highest in this window)
Plan to start buprenorphine, methadone, or extended-release naltrexone — induction timing is sensitive, especially with fentanyl on board
Eating disorder, low body weight, or marginal nutrition (less reserve for the dehydration phase)

What to expect next 24–72 hours

Short-acting opioids: the patient feels worst at 36–72 hours and substantially better by day 5–7, with sleep and energy still off for weeks. Fentanyl: do not assume the patient 'should be feeling better by now' at 48 hours — many describe peak symptoms later, with a longer tail. Methadone: a slow ramp that doesn't peak until day 3–4 and can stay rough for two weeks. The post-acute period is the highest-overdose-risk window of the patient's life because tolerance drops fast — naloxone should be in the home and the patient and family should know how to use it.

Subtleties non-specialists routinely miss

Fentanyl era: onset and peak can be later than older opioid timelines predict. This matters for buprenorphine induction — starting buprenorphine before the patient is clearly in withdrawal can precipitate severe withdrawal. Facility protocols and MOUD prescribers handle the timing; the recognition piece is just to expect variability and delay.
Lost tolerance is the single most important post-detox safety message. Overdose mortality spikes in the first 2 weeks after inpatient detox or incarceration release — give the naloxone-in-the-home talk every time.
Patients who use kratom, tianeptine, or loperamide at high doses will have an opioid-pattern withdrawal that they may not describe as 'opioid' — ask directly.
Severity scales were calibrated in the pre-fentanyl era; a 'low score' in a fentanyl user with delayed onset doesn't mean they're fine, it may mean it's early.

Documentation language (adapt, don't copy)

Patient reports last opioid use [date/time, agent if known]. Objective findings consistent with opioid withdrawal include [mydriasis / piloerection / rhinorrhea / lacrimation / yawning / GI symptoms / specific vital signs]. Patient educated on lost-tolerance overdose risk and on availability of medications for opioid use disorder. Naloxone availability in the home [confirmed / arranged].

Sample phrasing for a non-prescribing clinician's note. Replace bracketed items with your observations. Not a template for diagnosis or scoring.

Sources

• SAMHSA TIP 63: Medications for Opioid Use Disorder (2021 update).
• Kosten TR, George TP. Sci Pract Perspect. 2002;1(1):13–20. Neurobiology of opioid dependence.
• Strang J et al. BMJ. 2003;326(7396):959–960. Loss of tolerance and overdose mortality after inpatient detoxification.
• Binswanger IA et al. N Engl J Med. 2007;356(2):157–165. Mortality after release from prison — lost-tolerance window.
• ACOG Committee Opinion 711: Opioid Use and Opioid Use Disorder in Pregnancy.
• Antoine D et al. J Addict Med. 2021. Clinical observations on buprenorphine induction in the fentanyl era.

Benzodiazepines & other sedatives

Looks like alcohol withdrawal but slower, longer, and more unpredictable — especially with long-acting agents that can peak a week after the last dose.

Benzodiazepine withdrawal can be life-threatening and is frequently underestimated because the time course is so much longer than alcohol withdrawal. Includes z-drugs (zolpidem, eszopiclone), barbiturates, and GHB/GBL, which share the same GABA-A pathway. Abrupt discontinuation is generally unsafe; the standard of care is a slow taper, often with substitution to a longer-acting agent, in a medical setting for high-risk patients.

Onset

Short-acting (alprazolam, lorazepam): 1–2 days. Long-acting (diazepam, clonazepam): 2–7 days.

Peak

Variable; long-acting agents can peak a week or more after last dose because of active metabolites.

Duration

Acute symptoms commonly persist 2–4 weeks. Protracted anxiety, perceptual disturbance, and insomnia can last months.

Time course

Short-acting (alprazolam, lorazepam, oxazepam)

Onset 24h–2d · Peak 2d–4d · Resolves 14d–28d

02w3w28d

Onset windowPeak / danger windowResolving

Fastest onset, sharpest peak. Highest seizure risk window roughly day 2–5.

Long-acting (diazepam, clonazepam, chlordiazepoxide)

Onset 2d–7d · Peak 5d–10d · Resolves 21d–42d

02w3w42d

Onset windowPeak / danger windowResolving

Late-onset trap: peak can hit after the team has 'moved on.' Watch window must extend past day 7.

GHB / GBL / 1,4-BD

Onset 1h–6h · Peak 24h–3d · Resolves 7d–14d

03d1w2w3w

Onset windowPeak / danger windowResolving

Very rapid onset, high risk of severe withdrawal with delirium and autonomic instability — medical setting from the start.

Timelines are general clinical ranges, not patient-specific predictions. Individual courses vary with dose, duration of use, metabolism, and co-occurring substances.

What you'd observe

Tier 1

First 1–3 days (short-acting) / 2–5 days (long-acting)

Rebound anxiety, restlessness, irritability
Insomnia, vivid dreams
Fine tremor
Heart rate and blood pressure trending up
Heightened sensitivity to light, sound, touch
Headache, muscle tension

Tier 2

Building

Pronounced anxiety, panic episodes
Sweating, nausea, GI upset
Perceptual changes (things look 'off,' visual trails, mild depersonalization)
Concentration and short-term memory problems
Coarse tremor, muscle twitching

Tier 3

Dangerous

Withdrawal seizure (can happen even in patients with no prior seizure history)
Frank hallucinations, paranoia, psychotic features
Delirium with disorientation, agitation, autonomic instability
Catatonia or persistent altered mental status (less common but described)

Red flags — call now

Specific acute triggers for this substance

Witnessed or suspected seizure
New hallucinations, paranoia, or marked disorientation
Vital signs significantly elevated or unstable
Anyone discontinuing daily long-term benzodiazepines without a tapering plan and prescriber involvement
GHB withdrawal of any severity — medical setting from the start

Standing risk factors that lower the threshold for a medical setting

Long-term daily benzodiazepine use, especially at higher doses
Any prior withdrawal seizure on any substance
Combined sedative use (benzodiazepines + alcohol; benzodiazepines + z-drugs; GHB)
Older adults — falls and delirium risk are amplified
Pregnancy
Plan to discontinue abruptly without a structured taper

What to expect next 24–72 hours

If a taper is in place, the patient typically experiences waves of symptoms that crest after each dose reduction and settle over days. Without a taper, short-acting agents produce the sharpest, earliest crisis (day 2–5). Long-acting agents are the dangerous trap — the patient may feel relatively okay through day 4 or 5 and then deteriorate as the active metabolites finally clear. Acute symptoms commonly persist 2–4 weeks. A subset of patients have protracted symptoms (anxiety, insomnia, perceptual disturbance) lasting months — this is real, not malingering, and worth naming to the patient.

Subtleties non-specialists routinely miss

Late-onset trap with long-acting agents: a patient who looks fine on day 3 can seize on day 7. The watch window must extend, and outpatient handoffs should warn the patient and family explicitly.
Kindling applies here as it does to alcohol — each prior taper failure tends to make the next worse. Build slower tapers for patients with that history.
Z-drugs (zolpidem, eszopiclone, zopiclone) act at the same GABA-A site and cause the same withdrawal syndrome at high or long-term use — do not assume they are 'just sleep aids.'
GHB withdrawal is a distinct and dangerous entity: rapid onset (hours, not days), high rate of delirium and autonomic instability, and frequent need for high-dose sedation protocols. Always medical setting.
Protracted withdrawal (months of anxiety, perceptual disturbance, insomnia) is well-documented and often misread as 'the original anxiety came back.' Worth naming.

Documentation language (adapt, don't copy)

Patient reports [agent, dose, duration, last dose date/time]. Objective findings consistent with sedative-hypnotic withdrawal include [tremor / autonomic signs / perceptual disturbance / specific vitals]. Given [risk factors], abrupt discontinuation is contraindicated; plan includes prescriber-managed taper in [outpatient with monitoring / medically supervised setting], based on clinician judgment. Patient and family educated on the late-onset risk window for [long-acting agent].

Sample phrasing for a non-prescribing clinician's note. Replace bracketed items with your observations. Not a template for diagnosis or scoring.

Sources

• Ashton CH. J Subst Abuse Treat. 1991;8(1-2):19–28. Protracted withdrawal syndromes from benzodiazepines.
• Schep LJ et al. Clin Toxicol. 2012;50(6):458–470. GHB clinical toxicology and withdrawal.
• Pétursson H. Addiction. 1994;89(11):1455–1459. The benzodiazepine withdrawal syndrome.
• SAMHSA TIP 45: Detoxification and Substance Abuse Treatment — sedative-hypnotic chapter.

Stimulants (cocaine, methamphetamine, prescription stimulants)

Crash, then a long flat depressive valley. Rarely physiologically dangerous — the danger is suicide and persistent psychosis.

Stimulant withdrawal is rarely a medical emergency in the way alcohol or benzodiazepine withdrawal can be. The dominant clinical risks are psychiatric: acute suicidality (especially in the first 1–2 weeks of methamphetamine withdrawal) and stimulant-induced psychosis that can persist or re-emerge after the substance is gone. Screen for safety early and often. There is currently no FDA-approved medication for stimulant use disorder; behavioral interventions (contingency management has the strongest evidence) carry the load.

Onset

Within hours of last use

Peak

1–3 days (crash phase)

Duration

Acute crash 3–10 days. Anhedonia, low energy, cravings, and disturbed sleep can persist 4–10 weeks.

Time course

Stimulant withdrawal

Onset 2h–12h · Peak 24h–3d · Resolves 7d–70d

070d

Onset windowPeak / danger windowResolving

Short acute crash; long flat 'withdrawal phase' of low mood, cravings, and disrupted sleep that can run weeks to months.

Timelines are general clinical ranges, not patient-specific predictions. Individual courses vary with dose, duration of use, metabolism, and co-occurring substances.

What you'd observe

Tier 1

Crash (first 1–3 days)

Marked fatigue and very long sleep periods
Sharp increase in appetite
Low mood, irritability, flat affect
Vivid, sometimes disturbing dreams
Slowed thinking and movement

Tier 2

Withdrawal phase (days to weeks)

Persistent depressed mood, anhedonia, loss of motivation
Intense cravings, often triggered by people/places/cues
Difficulty concentrating, sluggish thinking
Disturbed sleep architecture even when total sleep looks adequate
Social withdrawal

Tier 3

Concerning

Suicidal ideation, especially with intent or plan
Severe depression interfering with self-care (not eating, not getting out of bed for days)
Persistent or re-emergent psychotic symptoms (paranoia, hallucinations, delusions) after the substance is gone
Aggressive behavior or homicidal ideation

Red flags — call now

Specific acute triggers for this substance

Any suicidal statement with intent or plan, or any active safety concern
New or worsening psychotic symptoms (paranoia, hallucinations, delusions) after the substance has cleared
Severe depression with inability to perform basic self-care
Homicidal ideation or significant agitation
Chest pain, seizure, or significant cardiovascular symptoms during use or immediately after (toxicity rather than withdrawal, but the same call)

Standing risk factors that lower the threshold for a medical setting

Methamphetamine use specifically — suicide risk is highest in the first 2 weeks of abstinence
Prior history of stimulant-induced psychosis (it tends to return faster and more severely with each episode)
Co-occurring mood disorder (bipolar, MDD) — stimulants often mask underlying mood pathology that surfaces in withdrawal
Recent psychotic break of any kind
Co-use with opioids — the opioid withdrawal phase masks the stimulant psychiatric phase initially
Pregnancy — stimulant use raises obstetric and neonatal risks; withdrawal is a moment to engage care

What to expect next 24–72 hours

The crash typically lasts 3–10 days — the patient is exhausted, sleeps a great deal, eats heavily, and feels emotionally flat. The withdrawal phase that follows is the harder and longer piece: weeks of low mood, low energy, intense cravings, and disturbed sleep. This is when relapse risk peaks and where structured support, accountability, and behavioral treatment matter most. Mood typically lifts gradually over 4–10 weeks of sustained abstinence, though some patients have a longer recovery curve. Recurrent psychosis can take longer to resolve and may need psychiatric medication and follow-up.

Subtleties non-specialists routinely miss

The dangerous part is psychiatric, not autonomic. The patient who looks 'just tired' may be acutely suicidal — ask directly, every visit, for at least the first two weeks.
Methamphetamine-induced psychosis can persist for weeks or recur with re-exposure; treat it as a real psychiatric diagnosis, not a 'just from the drugs' transient.
Stimulants frequently co-occur with opioid use. After acute opioid withdrawal resolves, the stimulant withdrawal phase may emerge next, including suicide risk.
There is no validated detox medication regimen analogous to alcohol or opioid withdrawal. Settings exist for safety (suicide risk, psychosis), not for symptom control.

Documentation language (adapt, don't copy)

Patient reports last [stimulant] use [date/time]. Findings consistent with stimulant withdrawal include [hypersomnia / increased appetite / depressed mood / anhedonia / specific safety findings]. Suicide and homicide risk assessed: [findings]. Psychosis screen: [findings]. Plan includes [safety planning / behavioral treatment referral / psychiatric follow-up if indicated].

Sample phrasing for a non-prescribing clinician's note. Replace bracketed items with your observations. Not a template for diagnosis or scoring.

Sources

• Glasner-Edwards S et al. Drug Alcohol Depend. 2009. Suicide risk in methamphetamine dependence.
• McKetin R et al. Addiction. 2006 and subsequent. Methamphetamine-associated psychosis.
• Newton TF et al. Biol Psychiatry. 2004. Methamphetamine abstinence syndrome — phenomenology.
• SAMHSA TIP 33: Treatment for Stimulant Use Disorders (updated 2021).

Cannabis

Real syndrome in daily heavy users, especially with concentrates — sleep disturbance, irritability, anxiety, and GI upset for 1–3 weeks. Not dangerous; routinely under-recognized.

Cannabis withdrawal was formally recognized in DSM-5 (2013) and is well-documented in heavy daily users, particularly with high-THC concentrates and vape products. It is not medically dangerous. The reason to include it: clinicians routinely tell patients 'cannabis isn't addictive' and miss the syndrome, which then drives relapse the patient and family don't understand.

Onset

24–72 hours after last use

Peak

Days 2–6

Duration

Most symptoms resolve in 1–3 weeks. Sleep disturbance and vivid dreams can persist 4+ weeks.

Time course

Cannabis withdrawal

Onset 24h–3d · Peak 2d–6d · Resolves 7d–21d

01w2w3w

Onset windowPeak / danger windowResolving

Sleep symptoms can outlast the rest of the syndrome by weeks.

Timelines are general clinical ranges, not patient-specific predictions. Individual courses vary with dose, duration of use, metabolism, and co-occurring substances.

What you'd observe

Tier 1

First 1–3 days

Irritability, anger, low frustration tolerance
Increased anxiety
Difficulty falling asleep; vivid, sometimes unpleasant dreams
Decreased appetite
Restlessness

Tier 2

Building (days 2–6)

Depressed mood
Stomach upset, nausea, GI cramping
Headache
Mild tremor, sweating, chills
Marked sleep disturbance — total sleep often quite reduced

Tier 3

Worth attention

Cannabinoid hyperemesis: cyclical severe vomiting, often relieved by hot showers — a separate entity that can require ED management for dehydration
Severe mood disturbance, especially in patients with co-occurring depression or anxiety disorders
Persistent or worsening symptoms beyond 4 weeks — consider co-occurring conditions or other substances

Red flags — call now

Specific acute triggers for this substance

Cyclical severe vomiting with inability to keep down fluids (suspect cannabinoid hyperemesis — needs ED for hydration and antiemetics)
Suicidal ideation with intent or plan
Severe dehydration signs

Standing risk factors that lower the threshold for a medical setting

Daily heavy use, especially with concentrates / dabs / high-THC vape
Co-occurring anxiety or depressive disorder (the syndrome unmasks them)
History of cannabinoid hyperemesis syndrome
Pregnancy — withdrawal is not dangerous but is an engagement opportunity

What to expect next 24–72 hours

Symptoms typically begin in the first day or two off, peak around days 2–6, and substantially resolve over 1–3 weeks. Sleep is the slowest piece — patients often report poor sleep and intense dreams for several weeks. Knowing this in advance helps patients ride it out without re-using to sleep, which is the common relapse path.

Subtleties non-specialists routinely miss

Concentrates and high-THC vape products produce a more severe withdrawal than flower — old assumptions ('cannabis isn't addictive') don't hold for daily concentrate users.
Sleep disturbance is the most common driver of relapse — patients use cannabis to sleep, then can't sleep without it, then re-use. Sleep hygiene support and short-term non-controlled sleep aids matter.
Cannabinoid hyperemesis syndrome is distinct — cyclical vomiting in heavy users, often with the characteristic hot-shower relief pattern. Resolves with abstinence; can recur immediately on re-use.
Patients and families often need explicit education that this is a real syndrome — clinical legitimacy reduces the 'just toughen up' framing.

Documentation language (adapt, don't copy)

Patient reports last cannabis use [date/time]; pattern [daily / multiple times daily / concentrate use]. Findings consistent with cannabis withdrawal include [sleep disturbance / irritability / anxiety / appetite changes / GI symptoms]. Patient educated that this is a recognized syndrome and typically resolves over 1–3 weeks, with sleep recovering more slowly.

Sample phrasing for a non-prescribing clinician's note. Replace bracketed items with your observations. Not a template for diagnosis or scoring.

Sources

• Bonnet U, Preuss UW. Subst Abuse Rehabil. 2017;8:9–37. Cannabis withdrawal syndrome — systematic review.
• Budney AJ, Hughes JR. Curr Opin Psychiatry. 2006;19(3):233–238. Cannabis withdrawal syndrome.
• American Psychiatric Association. DSM-5 (2013) and DSM-5-TR (2022). Cannabis withdrawal diagnostic criteria.
• Sorensen CJ et al. J Med Toxicol. 2017. Cannabinoid hyperemesis syndrome review.

Kratom

Mild opioid-pattern withdrawal in regular users. Increasingly common; patients often don't volunteer kratom use — ask directly.

Kratom's main alkaloid mitragynine is a partial mu-opioid receptor agonist. Heavy or long-term users develop physiologic dependence and an opioid-pattern withdrawal syndrome — usually milder than heroin/oxycodone withdrawal but the same general shape. Worth including because (a) kratom is sold in convenience stores and not perceived as an opioid by patients or many clinicians, (b) it's increasingly common in patients with prior opioid use disorder using it for self-management.

Onset

12–24 hours after last use

Peak

Days 2–4

Duration

Most symptoms resolve in 5–10 days; mood and sleep can persist longer.

Time course

Kratom withdrawal

Onset 12h–24h · Peak 2d–4d · Resolves 5d–10d

03d1w10d

Onset windowPeak / danger windowResolving

Looks like a milder opioid withdrawal; same general shape and timeline.

Timelines are general clinical ranges, not patient-specific predictions. Individual courses vary with dose, duration of use, metabolism, and co-occurring substances.

What you'd observe

Tier 1

First 12–24 hours

Anxiety, restlessness, irritability
Runny nose, watery eyes
Sweating, chills
Muscle aches
Yawning

Tier 2

Building (days 2–4)

Muscle and joint aches
Abdominal cramping, nausea, loose stools
Insomnia, intense cravings
Low mood, dysphoria

Tier 3

Concerning

Significant dehydration from GI symptoms (less common than with strong opioids but possible)
Severe mood disturbance, suicidal ideation
Co-occurring withdrawal from other opioids that the patient hasn't disclosed

Red flags — call now

Specific acute triggers for this substance

Inability to keep down fluids
Suicidal ideation with intent or plan
Pregnancy with any withdrawal symptoms

Standing risk factors that lower the threshold for a medical setting

Daily use, especially at high doses or with high-mitragynine extract products
Concurrent or prior opioid use disorder
Use during pregnancy
Co-use with other opioids, benzodiazepines, or alcohol

What to expect next 24–72 hours

Many kratom users describe a withdrawal that feels like 'mild flu' for 5–10 days. Mood, sleep, and cravings can persist beyond that. Case reports describe medication support, including buprenorphine in selected cases, but there is no FDA-approved treatment for kratom dependence — refer to an addiction-medicine prescriber if the patient wants medication support.

Subtleties non-specialists routinely miss

Ask about kratom directly by name in any substance history — patients regularly omit it because they categorize it as 'herbal' or 'legal.'
Kratom extracts and concentrated 'shot' products have far higher mitragynine content than traditional leaf, and produce correspondingly more severe withdrawal.
Medication support for kratom dependence is prescriber territory; case reports describe buprenorphine, but the evidence base is limited.
Some patients use kratom specifically to self-manage prior opioid use disorder; the conversation about formal MOUD is often welcome.

Documentation language (adapt, don't copy)

Patient reports kratom use [pattern, daily dose if known, last use date/time]. Findings consistent with opioid-pattern withdrawal include [specifics]. Patient educated that medication support for kratom dependence is an addiction-prescriber question with limited evidence; [referral arranged if applicable].

Sample phrasing for a non-prescribing clinician's note. Replace bracketed items with your observations. Not a template for diagnosis or scoring.

Sources

• Singh D, Müller CP, Vicknasingam BK. Drug Alcohol Depend. 2014;139:132–137. Kratom dependence, withdrawal, and craving.
• Galbis-Reig D. WMJ. 2016;115(1):49–52. Kratom withdrawal — case reports and review.
• Eastlack SC et al. Adv Ther. 2020;37(1):20–43. Kratom — pharmacology, clinical implications, and outlook.
• FDA communications on kratom (multiple, 2017–present) — regulatory and adverse-event context.